Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Cooperative Oncology Group
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
Age
18–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
\- women \>18 years old with advanced high grade ovarian cancer
You may not be if
\-
Clareo Health | Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
